Phase 3 – Page 8 – Communicable Diseases Research

Influence of APOE locus on poor prognosis of COVID-19

Research Article

Published on 2021-06-232022-10-31
Journal: Heliyon [Category] COVID-19,

[키워드] 1000 Genomes Project allele allele frequency Alter Analysis ApoE blocks clinical outcomes composed COVID-19 COVID-19 pandemic Critical death decrease disequilibrium distribution European European population expression expression level Frequency Gene Expression Genetic greater Haplotype higher impact immune response indicate influence investigated involved linkage locus lung lung tissue Lungs modulating MOST Phase 3 poor prognosis Population Prognosis Protein recent risk SARS-CoV-2 SARS-COV-2 infection Seven severe COVID-19 significantly susceptibility susceptible tissue damage variant was obtained
[DOI] 10.1016/j.heliyon.2021.e07379 PMC 바로가기 [Article Type] Research Article

A Summary of the SARS-CoV-2 Vaccines and Technologies Available or under Development

Review

Published on 2021-06-222022-10-28
Journal: Pathogens [Category] COVID-19,

Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women

임산부와 수유부에서 코로나19 mRNA 백신의 면역원성

Article

Published on 2021-06-152022-09-11
Journal: JAMA [Category] MERS, SARS, 변종, 진단,

[키워드] antibody Antibody Response Antibody titers assays B.1.1.7 B.1.351 B.1.351 variant B.1.351 variants binding binding and neutralizing antibodies binding domain Blood BNT162b2 breast milk CD4 CD8 T-cell response CD8 T-cell responses Cellular immune response Cord blood COVID-19 COVID-19 vaccine COVID-19 vaccine trials COVID-19 vaccines cross-reactive antibody enrolled enzyme enzyme-linked immunospot evaluate evaluated excluded exploratory Exploratory analysis Fever Follow-up functional Humoral and cellular immune responses IFN-γ immune responses immunogenic immunogenicity ImmunoSpot increased risk lactating lactating women Messenger RNA Moderna morbidity morbidity and mortality mRNA mRNA vaccine mRNA-1273 Neutralizing Neutralizing antibodies neutralizing antibody Neutralizing antibody titer neutralizing antibody titers nonpregnant outcome Pfizer-BioNTech Phase 3 Population pregnant pregnant women preserved prospective cohort study receipt reduced reported response SARS-CoV-2 B.1.1.7 SARS-COV-2 infection SARS-CoV-2 receptor SARS-CoV-2 USA-WA1/2020 SARS-CoV-2 variant SARS-CoV-2 variants Spike-specific T-cell responses T-cell Response T-cell responses the SARS-CoV-2 transported vaccination Vaccine vaccine dose Viral Viral variants were assessed white women
[DOI] 10.1001/jama.2021.7563 PMC 바로가기 [Article Type] Article

Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and Authorization

Tozinameran (BNT162B2) 백신 : 전임상 연구에서 임상 시험 및 승인으로의 여정

Review

Published on 2021-06-072022-08-31
Journal: AAPS PharmSciTech [Category] MERS, SARS, 신약개발, 임상, 진단,

[키워드] Administered administration adolescents adverse effects age antibody Antibody Response authorization bind BioNTech BNT162b1 BNT162b2 BNT162b2 vaccine BNT162b2 vaccines children clinical clinical trial clinical trials COVID-19 dosages Efficacy ENCODE EUA exhibited expected expression first dose host cells immune response Immunity individual Lipid nanoparticle Lipid nanoparticles mRNA Neutralizing antibodies of BNT162b2 Older operation participant Pfizer Pfizer-BioNTech Phase 1 phase 1 trials phase 1/2 trials Phase 2 phase 2 trials phase 2/ 3 trials phase 2/3 Phase 3 Phase 3 trials Preclinical preclinical studies preclinical trials pregnant pregnant women question real-world outcomes receive reported RNA robust S antigen Safety SARS-CoV-2 SARS-CoV-2 spike protein speed Spike protein Support the SARS-CoV-2 Tozinameran transfer Trial Vaccine
[DOI] 10.1208/s12249-021-02058-y PMC 바로가기 [Article Type] Review

COVID-19 vaccines: Frequently asked questions and updated answers

Review article

Published on 2021-06-012022-10-05
Journal: Infectious diseases now [Category] 비임상,

MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study

Article

Published on 2021-05-102022-10-04
Journal: Nature Medicine [Category] 임상,

[키워드] 1:1 3,4-methylenedioxymethamphetamine Adverse adverse event alcohol baseline childhood clinical evaluation clinical trial Comorbidity decrease Depression disability disorder double-blind Drug development DSM-5 effective Efficacy and safety event functional impairment inactive individual induce MDMA medication nine participant Patient Phase 3 phase 3 study Phase III trials Placebo placebo-controlled placebo-controlled trial Post-traumatic stress disorder Psychiatric PTSD public health QT prolongation Randomized receive Result robust Safe scale SDS secondary endpoint significantly Stress substance use disorders Symptoms the placebo group the primary endpoint therapy those with comorbidities total score trauma Treatment were assessed
[DOI] 10.1038/s41591-021-01336-3 PMC 바로가기 [Article Type] Article

COVID‐19: vaccine’s progress

Lilliput

Published on 2021-05-072022-10-30
Journal: Microbial Biotechnology [Category] COVID-19,

[키워드] clinical trials COVID‐19 disease inactivated mRNA vaccines National pandemic Phase 3 platform Preclinical Testing produced recombinant protein vaccine vaccination Vaccine Vaccines whole virus vaccine
[DOI] 10.1111/1751-7915.13818 PMC 바로가기 [Article Type] Lilliput

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study

Observational Study

Published on 2021-05-012022-10-04
Journal: Lancet (London, England) [Category] Fulltext, MERS, 임상,

[키워드] 95% CI age Analysis association BNT162b2 mRNA BNT162b2 mRNA vaccine ChAdOx1 nCoV-19 ChAdOx1 vaccine challenge clinical trial COVID-19 COVID-19 vaccination COVID-19 vaccine Cox model defined disease Effect Effectiveness Efficacy enhanced finding first dose funding Hospital admission individual Industrial Innovation Interim mass Medical Research Council National Older Patient Pfizer–BioNTech Phase 3 Poisson regression model positive primary care prospective cohort study reduced Registered residual confounding Result reverse transcription-PCR risk shown Strategy study period substantial reduction tested vaccination Vaccine were excluded
[DOI] 10.1016/S0140-6736(21)00677-2 PMC 바로가기 [Article Type] Observational Study

Interim estimates in null models of COVID-19 vaccine effectiveness

COVID-19 백신 효과의 null 모델에 대한 중간 추정치

Article

Published on 2021-05-012022-09-11
Journal: International Journal of Infectious Diseases [Category] SARS, 임상,

Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment

Review article

Published on 2021-05-012022-10-05
Journal: Vaccine [Category] SARS, 비임상,

[키워드] Ad26 adenoviral vector Adenovirus baseline Benefit/Risk cellular immune responses Characteristics clinical clinical evaluation clinical study clinical trials collaboration COVID-19 vaccine database Ebola virus effective evaluate evaluated Express expression Extensive feature FIVE flexible Genetic group Human humoral key consideration mammalian cell Neutralizing antibody titer New participant Phase 3 platform pre-existing immunity profiles regimen Replication Replication-incompetent Ad26 risk Safety T cell response transgene Trial Vaccine Vaccine development vaccine immunogenicity Vaccines variety vector vectors Viral vector Viral vector vaccines working
[DOI] 10.1016/j.vaccine.2020.09.018 [Article Type] Review article